Evidence map›Paper›PMID 27494859›Full record

ArticleOncotarget2016

MiRNA-22 inhibits oncogene galectin-1 in hepatocellular carcinoma.

Yu You, Jia-Xin Tan, Hai-Su Dai, Hao-Wei Chen, Xue-Jun Xu, Ai-Gang Yang, Yu-Jun Zhang, Lian-Hua Bai, Ping Bie

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 2 pooled it
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 2 syntheses or guidelines pooled it, 50 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Review
  7. Pancreatic MicroRNAs inBiomolecules · 2025
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Yu YouDepartment of Hepatobiliary Surgery Institute, South Western Hospital, Third Military Medical University, Chongqing 400038, China.
Jia-Xin TanDepartment of Hepatobiliary Surgery Institute, South Western Hospital, Third Military Medical University, Chongqing 400038, China.
Hai-Su DaiDepartment of Hepatobiliary Surgery Institute, South Western Hospital, Third Military Medical University, Chongqing 400038, China.
Hao-Wei ChenDepartment of Hepatobiliary Surgery Institute, South Western Hospital, Third Military Medical University, Chongqing 400038, China.
Xue-Jun XuDepartment of Hepatobiliary Surgery Institute, South Western Hospital, Third Military Medical University, Chongqing 400038, China.
Ai-Gang YangDepartment of Hepatobiliary Surgery Institute, South Western Hospital, Third Military Medical University, Chongqing 400038, China.
Yu-Jun ZhangDepartment of Hepatobiliary Surgery Institute, South Western Hospital, Third Military Medical University, Chongqing 400038, China.
Lian-Hua BaiDepartment of Hepatobiliary Surgery Institute, South Western Hospital, Third Military Medical University, Chongqing 400038, China.
Ping BieDepartment of Hepatobiliary Surgery Institute, South Western Hospital, Third Military Medical University, Chongqing 400038, China.
Army Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatic stellate cells (HSCs) induce immune privilege and promote hepatocellular carcinoma (HCC) by suppressing the immune system. On the other hand, galectin-1 and miRNA-22 (miR-22) are dysregulated in HCC and serve as prognostic indicators for patients. In this study, therefore, we measured galectin-1 and miR-22 expression in HSCs isolated from HCC tissues (Ca-HSCs), and in normal liver tissues (N-HSCs) as a control. We also investigated the apoptosis rate among T cells and the production of cytokines (IFN-γ and IL-10) in HSCs co-cultured with T cells. And we used immunohistochemical staining to tested for correlation between galectin-1 expression, CD3 expression and clinicopathological features in 162 HCC patients. Our results showed that galectin-1 expression was much higher in Ca-HSCs than in N-HSCs. Overexpression of galectin-1 promoted HSC-induced T cell apoptosis and cytokine production (IFN-γ and IL-10), while miR-22 expression inhibited it. Galectin-1 expression correlated negatively with miR-22 expression in HSCs. High galectin-1 and low CD3 expression levels were associated with poor prognosis in HCC patients. These results suggest that the immunosuppressive microenvironment promoted by HSC-derived galectin-1 in HCC can be inhibited by miR-22. Galectin-1 and miR-22 could potentially serve as prognostic markers and therapeutic targets in HCC.

Indexed as

Gene Expression Regulation, NeoplasticActinsAgedApoptosisCarcinoma, HepatocellularCD3 ComplexCell Line, TumorCytokinesFemaleGalectin 1Gene Expression ProfilingHumansInterferonsInterleukin-10K562 CellsLiverActinsCD3 ComplexCytokinesGalectin 1IL10 protein, humanInterferonsInterleukin-10LGALS1 protein, humanMicroRNAsMIRN22 microRNA, humangalectin-1hepatic stellate cellshepatocellular carcinomamiRNA-22

Identifiers

PMID27494859
PMCPMC5302976
OpenAlexW2509197499

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.